Evaxion's AI Platform Shows Scalability for Glioblastoma Vaccine Development

summarizeSummary

Evaxion announced new data demonstrating its AI-Immunology™ platform's ability to identify novel targets for glioblastoma vaccines, including endogenous retrovirus-derived antigens, which will be presented at AACR.

check_boxKey Events

• AI Platform Scalability Confirmed

  New data demonstrates the AI-Immunology™ platform's unique scalability for developing vaccines, specifically for glioblastoma.

• Novel Glioblastoma Targets Identified

  The platform successfully identified endogenous retrovirus (ERV)-derived antigens in glioblastoma tumor samples, offering a new source of targets for cancer vaccines.

• Collaboration with Duke University

  Data analysis was conducted in collaboration with researchers at Duke University School of Medicine.

• AACR Presentation Scheduled

  The new data will be presented at the American Association for Cancer Research (AACR) Annual Meeting on April 22, 2026.

auto_awesomeAnalysis

This filing highlights a significant expansion of Evaxion's AI-Immunology™ platform, demonstrating its unique scalability and potential to develop vaccines for glioblastoma, a deadly brain cancer with limited treatment options. The identification of endogenous retrovirus (ERV)-derived antigens as novel targets is particularly important, as glioblastoma typically has a low mutational burden, making traditional neoantigen targeting challenging. This "Proof-of-Concept" data, developed in collaboration with Duke University, validates the platform's versatility and opens new avenues for personalized cancer vaccine strategies, potentially enhancing efficacy for patients with high unmet medical needs. The presentation at the AACR Annual Meeting will provide further visibility and discussion opportunities with scientific and business partners.